Search
ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.
Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.
Read moreDo generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.
The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.
Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.
Abstract S722
Acute lymphoblastic leukemia (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.
Gdf -11 a new target to improve anemia in thalassemia.
β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.
Can Eltrombopag help children with ITP say goodbye to bleeding?
Immune thrombocytopenia (ITP) is a rare disease in children, affecting 5 in 100,000. Most children get better quickly without intervention but up to 30% will still have disease at 12 months.
Pivotal Ruxolitinib Data Shows Promise for Patients with PV.
Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.
Mutiple Myeloma at the 19th Congress of the European Hematology Association: What is new?
During the meeting, recently developed approaches for diagnosis and monitoring will be presented. Gene-expression-profiling to detect molecular subgroups with a different prognosis and high-throughput-sequencing to identify new genetic lesions will be discussed.
Read moreHarnessing new developments in genomics to improve outcome for children with poor prognosis leukemia
At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.
Read moreAdvances from genome sequencing are paving the way to personalized treatment for leukemia and pre-leukemia
In acute myeloid leukemia (AML) our understanding of how modifications to DNA molecules that do not result in sequence change (i. e.
Read moreLeading Medical Organizations Join Forces Globally to Launch First-Ever World Thrombosis Day
“We must reduce the burden from thrombosis if we are to achieve the World Health Assembly’s global target of reducing mortality from premature non-communicable disease by 25 percent by 2025,” said Gary Raskob, Ph. D.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- »